PierianDx enables health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual's DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx's proprietary Clinical Genomicist Workstation provides clinical labs more streamlined and accurate analysis, interpretation, and reporting needed to accelerate their personalized medicine programs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/16 | $9,250,000 | Series A |
ARUP Laboratories Health Catalyst Capital Management Inova Translational Medicine Institute Ocean Road Advisors | undisclosed |
